Domiciliary Transcutaneous Electrical Stimulation Safe, Effective for Sleep Apnea
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 18, 2023 -- For patients with obstructive sleep apnea (OSA), domiciliary transcutaneous electrical stimulation (TESLA) can be used safely and effectively, according to a study published online Aug. 3 in eClinicalMedicine.
Deeban Ratneswaran, M.B.B.S., from King's College London, and colleagues conducted a single-center, randomized, phase 3 trial involving patients with OSA, body mass index of 18.5 to 32 kg/m2, and documented lack of adherence to continuous positive airway pressure (CPAP) therapy. Patients were randomly assigned to receive TESLA or usual care (CPAP) for at least three months (29 and 27, respectively). Change in apnea-hypopnea index (AHI) at three months was measured as the primary outcome.
The researchers found that in an unadjusted analysis, the group difference in the ΔAHI was −11.5 h−1. The difference was ΔAHI −7.0 h−1 in favor of the intervention after adjustment for the baseline value. One participant developed mild headaches related to the intervention.
"Domiciliary TESLA of the submental area is a feasible, safe and effective treatment for patients with OSA who do not tolerate CPAP in the long term, and provides a potential second line alternative treatment for patients to improve pathophysiology and control symptoms," the authors write.
One author is the named inventor on a patent for an "apparatus for treatment of snoring and sleep apnea"; a second author disclosed ties to Phillips Respironics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea
FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 -- Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study...
Sleep Apnea, Low Oxygen in Sleep Linked to Late-Onset Epilepsy
THURSDAY, May 2, 2024 -- Sleep apnea and late-midlife oxygen desaturation to less than 80 percent during sleep are associated with subsequent development of late-onset epilepsy...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.